B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes

Journal of Experimental Medicine

Volumn 183, Issue 3, 1996, Pages 791-800

  Johnston, Janet V ^a   Malacko, Alison R ^a   Mizuno, Mark T ^a   McGowan, Patrick ^a   Hellström, Ingegerd ^a   Hellström, Karl Erik ^a   Marquardt, Hans ^a   Chen, Lieping ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CELL STIMULATION; CYTOTOXIC T LYMPHOCYTE; GENE AMPLIFICATION; GENETIC ENGINEERING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; TARGET CELL;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY, ADOPTIVE; KINETICS; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0029920908     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.183.3.791     Document Type: Article

References (37)

1. June, C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today. 15:321-332.
2. Linsley, P.S., and J.A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191-212.
3. Mueller, D.L., M.K. Jenkins, and R.H. Schwartz. 1989. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:445-480.
4. Chen, L., P.S. Linsley, and K.E. Hellström. 1993. Costimulation of T cells for tumor immunity. Immunol. Today. 14.482-486.
5. Allison, J.P. 1994. CD28-B7 interactions in T cell activation. Curr. Opin. Immunol. 6:414-419.
6. Ostrand-Rosenberg, S. 1994. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 6:722-727.
7. Hellström, K.E., I. Hellström, and L. Chen. 1995. Can costimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145:123-145.
8. Chen, L., S. Ashe, W.A. Brady, I. Hellström, K.E. Hellström, J.A. Ledbetter, P. McGowan, and P.S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1093-1102.
9. + T cells by B7-transfected melanoma cells. Science (Wash. DC). 259:368-370.
10. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L.M. Nadler, G.J. Freeman, and L.H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA. 90:5687-5690.
11. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153:421-428.
12. Urban, J.L., and H. Schreiber. 1992. Tumor antigen. Annu. Rev. Immunol. 10:617-644.
13. Sercarz, E.E., P.V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1994, Dominance and cripticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729-766.
14. b-restricted cytotoxic T lymphocytes. J. Exp. Med. 175:545-552.
15. Houbiers, J.G., H.W. Nijman, S.H. van der Burg, J.W. Drijfhout, P. Kenemans, C.J. wan de Welde, A. Brand, F. Momburg, W.M. Kast, and C.J. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072-2077.
16. b cells. J. Immunol. 152:4843-4851.
17. Niedermann, G., S. Nutz, H.G. Ihlenfeldt, R. Grimm, M. Lucchiari, H. Hoschützky, G. Jung, B. Maier, and K. Eichmann. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity. 2:289-299.
18. b-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs. Eur. J. Immunol. 22:2663-2667.
19. Ressing, M.E., A. Sette, R.M. Brandt, J. Ruppert, P.A. Wentworth, M. Hartman, C. Oseroff, H.M. Grey, C.J. Melief, and W.M. Kast. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A(Black star sign)0201-binding peptides. J. Immunol. 154:5934-5943.
20. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W.M. Kast, C.J. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586-5592.
21. Schwartz, R.H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 71:1065-1068.
22. Harding, F.A., J.G. McArthur, J.A. Gross, D.H. Raulet, and J.P. Allison. 1992. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (Lond.). 356:607-609.
23. Gimmi, C.D., G.J. Freeman, J.G. Gribben, G. Gray, and L.M. Nadler. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci USA. 90:6586-6590.
24. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellström, and K.E. Hellström. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523-532.
25. Benjamim, E., S. Fong, C. Erickson, C.Y. Leung, D. Rennick, and R.J. Scibienski. 1977. Immunity to lymphoid tumors in syngeneic mice by immunization with mitomycin C-treated cells. J. Immunol. 118:685-93.
26. Visseren, M.J.W., M. Koot, E.I.H. van der Voort, L.A. Gravestein, H.J. Schoenmakers, W.M. Kast, M. Zijlstra, and C.J.M. Melief. 1994. Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J. Immunother. 15:119-128.
27. Allen, H., D. Wraith, P. Pala, B. Askonas, and R.A. Flavall. 1984. Domain interactions of H-2 class I antigens alter cytotoxic T-cell recognition sites. Nature (Lond.). 309:279-281.
28. Ljunggren, H.-G., and K. Kärre. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162:1745-1752.
29. Chen, L., M.T. Mizuno, M.C. Singhal, S.L. Hu, D.A. Galloway, I. Hellström, and K.E. Hellström. 1992. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J. Immunol. 148:2617-2621.
30. Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H.G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.). 351:290-296.
31. Finck, B.K., P.S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science (Wash. DC). 265:1225-1227.
32. Yang, G., K.E. Hellström, M. Mizuno, and L. Chen. 1995 In vitro priming of tumor-reactive cytolytic T lymphocytes by combining interleukin-10 with B7-CD28 costimulation. J. Immunol. 155:3897-3903.
33. Koeppen, H., M. Acena, A. Drolet, D.A. Rowley, and H. Schreiber. 1993. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur. J. Immunol. 23:2770-2776.
34. De Bruijn, M.J.H., T.N.M., Schumacher, J.D. Nieland, H.L. Ploegh, W.M. Kast, and C.J.M. Melief. 1991. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur. J. Immunol. 21:2963-2968.
35. Nonacs, R., C. Humborg, J.P. Tam, and R.M. Steinman. 1992. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J. Exp. Med. 176:519-529.
36. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P.G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:340-347.
37. Weinhold, K.H., D. Miller, and E.F. Wheelock. 1979. The tumor-dormant state: comparison of L5178Y cells used to establish dormancy with those that emerge following its termination. J. Exp. Med. 419:745-757.